AUTHORS
Donald C Moore, PharmD, BCOP, Pedro Fontes2, Martijn Simons3, Yves Mbous, PhD4, Huimin Li5, Tychell Branchcomb, PharmD6, Anthony Wang, PhD, MPH7, Abualbishr Alshreef, PhD, MSc, MPH8, Felipe Marques Gonçalves, MD, MBA9, Zhijie Ding, PhD, MSc, MBA10, Moshe Levy, MD11
AFFILIATIONS
1 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
2 OPEN Health, Rotterdam, Netherlands
3 OPEN Health, Rotterdam, Netherlands
4 AbbVie Inc., North Chicago, Illinois, United States
5 AbbVie Inc., North Chicago, Illinois, United States
6 Genmab US, Inc., Plainsboro, New Jersey, United States
7 AbbVie Inc., North Chicago, Illinois, United States
8 AbbVie Inc., North Chicago, Illinois, United States
9 Genmab US, Inc., Plainsboro, New Jersey, United States
10 Genmab US, Inc., Plainsboro, New Jersey, United States
11 Texas Oncology–Tyler, US Oncology Research, Dallas, Texas, United States
ABSTRACT
Introduction: Follicular lymphoma (FL) is the most common indolent lymphoma and the second most common non-Hodgkin lymphoma, accounting for 20–25% of all cases. The treatment landscape for relapsed/refractory (R/R) FL has recently evolved to include epcoritamab+rituximab and lenalidomide (R2) and tafasitamab+R2. In the phase 3 EPCORE FL-1 trial (NCT05409066), fixed-duration epcoritamab+R2 reduced the risk of progression or death by 79% and significantly improved time to next treatment (TTNT) vs R2 alone in patients with second-line or later (2L+) R/R FL. Despite treatment advances, data remain limited on the cost-effectiveness of treatment options in R/R FL. We evaluated the cost-effectiveness of epcoritamab+R2 vs R2, tafasitamab+R2, and chemoimmunotherapy (CIT; including rituximab/obinutuzumab (R/O)-bendamustine, R/O-cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP], and other options) in patients with 2L+ R/R FL from a US healthcare payer perspective.
Methods: A partitioned survival model was developed to estimate the cost-effectiveness of epcoritamab+R2 vs R2, tafasitamab+R2, and CIT in patients with 2L+ R/R FL. The model included 4 mutually exclusive health states: progression-free, progressed disease without initiation of next antilymphoma treatment, progressed disease with initiation of next treatment, and death. The proportions of patients in each health state were determined by progression-free survival (PFS), TTNT, and overall survival (OS) curves using an area-under-the-curve approach. PFS, TTNT, and OS for epcoritamab+R2 and R2 were derived from individual patient data (IPD) from EPCORE FL-1, where the relative efficacy was also estimated. For other comparators, IPD from EPCORE FL-1 was used to conduct an anchored matching adjusted indirect comparison vs tafasitamab+R2 (Linton K et al. HemaSphere. 2026;10:3660-2) and an inverse probability of treatment weighted analysis vs CIT (Falchi L et al. HemaSphere. 2026;10:3676-8). Extrapolation beyond study follow-up used standard parametric survival curves based on goodness-of-fit statistics. The model used a lifetime horizon, 28-day cycles, and half-cycle correction. Costs included treatment acquisition, treatment administration, treatment monitoring, pre- and post-progression medical costs, subsequent treatment, adverse event (AE) management, and terminal care. Time on treatment and time to treatment discontinuation were used to estimate drug acquisition costs; administration costs were based on treatment-specific administration requirements. Costs were reported in 2025 US dollars; costs and outcomes were discounted at 3% annually. Health-state utility values, age-related utility changes, and AE-related utility decrements were applied to estimate quality-adjusted life-years (QALYs). Model outputs included life-years (LYs), QALYs, total costs, incremental costs, and incremental cost-effectiveness ratios (ICERs), calculated as incremental cost per QALY. Scenario and sensitivity analyses were conducted to assess model robustness.
Results: In the lifetime horizon base case, mean undiscounted time spent progression-free and with progressed disease before next treatment was 5.62 and 7.12 years with epcoritamab+R2, respectively, compared with 1.99 and 0.68 years with R2, 3.02 and 3.94 years with tafasitamab+R2, and 1.98 and 1.08 years with CIT. Over a lifetime horizon, compared with R2, epcoritamab+R2 was associated with 4.95 incremental LYs, 3.81 incremental QALYs, and $289,367 in incremental costs, resulting in an ICER of $75,989/QALY gain. Compared with tafasitamab+R2, epcoritamab+R2 was associated with 2.31 incremental LYs, 1.78 incremental QALYs, and $126,167 in incremental costs, resulting in an ICER of $70,789/QALY gain. Compared with CIT, epcoritamab+R2 was associated with 8.77 incremental LYs, 6.50 incremental QALYs, and $253,222 in incremental costs, resulting in an ICER of $38,942/QALY gain. Sensitivity analyses and scenario analyses showed consistent findings.
Conclusions: Fixed-duration epcoritamab+R2 prolonged progression-free time, delayed next treatment initiation, and increased LYs and QALYs vs R2, tafasitamab+R2, and CIT. All ICERs were below the willingness-to-pay threshold of $150,000/QALY gained commonly used in the United States, supporting the economic value of fixed-duration epcoritamab+R2 as a cost-effective option from a US healthcare payer perspective and informing treatment decisions for patients with 2L+ R/R FL.
DISCLOSURES
Moshe Levy, MD: Johnson & Johnson - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)